Stock Scorecard
Stock Summary for Lexicon Pharmaceuticals Inc (LXRX) - $1.76 as of 1/23/2026 3:05:22 PM EST
Total Score
6 out of 30
Safety Score
11 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LXRX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LXRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LXRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LXRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LXRX (11 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 2 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for LXRX
Financial Details for LXRX
Company Overview |
|
|---|---|
| Ticker | LXRX |
| Company Name | Lexicon Pharmaceuticals Inc |
| Country | N/A |
| Description | Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical leader based in The Woodlands, Texas, focused on developing novel therapies for metabolic and neuroendocrine disorders. The company utilizes its proprietary gene-targeting technologies to advance a promising pipeline of innovative treatments aimed at addressing critical unmet medical needs. With an experienced leadership team and a commitment to scientific excellence, Lexicon is strategically positioned to improve patient outcomes while fostering long-term growth in the rapidly evolving healthcare landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/5/2026 |
Stock Price History |
|
| Last Day Price | 1.76 |
| Price 4 Years Ago | 1.91 |
| Last Day Price Updated | 1/23/2026 3:05:22 PM EST |
| Last Day Volume | 3,460,603 |
| Average Daily Volume | 2,180,235 |
| 52-Week High | 1.66 |
| 52-Week Low | 0.28 |
| Last Price to 52 Week Low | 528.57% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 25.93 |
| Sector PE | 128.28 |
| 5-Year Average PE | -4.83 |
| Free Cash Flow Ratio | 12.57 |
| Industry Free Cash Flow Ratio | 32.34 |
| Sector Free Cash Flow Ratio | 35.08 |
| Current Ratio Most Recent Quarter | 5.64 |
| Total Cash Per Share | 0.14 |
| Book Value Per Share Most Recent Quarter | 0.33 |
| Price to Book Ratio | 3.99 |
| Industry Price to Book Ratio | 56.10 |
| Sector Price to Book Ratio | 21.76 |
| Price to Sales Ratio Twelve Trailing Months | 6.72 |
| Industry Price to Sales Ratio Twelve Trailing Months | 58.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 28.33 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 363,399,000 |
| Market Capitalization | 639,582,240 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 6.42% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -63.40% |
| Annual Earnings Growth | -13.15% |
| Reported EPS 12 Trailing Months | -0.19 |
| Reported EPS Past Year | -0.10 |
| Reported EPS Prior Year | -0.64 |
| Net Income Twelve Trailing Months | -68,578,000 |
| Net Income Past Year | -200,403,000 |
| Net Income Prior Year | -177,119,000 |
| Quarterly Revenue Growth YOY | 710.00% |
| 5-Year Revenue Growth | -37.35% |
| Operating Margin Twelve Trailing Months | -85.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 49,656,000 |
| Total Cash Past Year | 66,656,000 |
| Total Cash Prior Year | 22,465,000 |
| Net Cash Position Most Recent Quarter | -6,852,000 |
| Net Cash Position Past Year | -33,642,000 |
| Long Term Debt Past Year | 100,298,000 |
| Long Term Debt Prior Year | 99,508,000 |
| Total Debt Most Recent Quarter | 56,508,000 |
| Equity to Debt Ratio Past Year | 0.59 |
| Equity to Debt Ratio Most Recent Quarter | 0.68 |
| Total Stockholder Equity Past Year | 145,950,000 |
| Total Stockholder Equity Prior Year | 93,110,000 |
| Total Stockholder Equity Most Recent Quarter | 120,159,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -72,583,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.20 |
| Free Cash Flow Past Year | -179,811,000 |
| Free Cash Flow Prior Year | -162,367,000 |
Options |
|
| Put/Call Ratio | 0.12 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.03 |
| MACD Signal | -0.02 |
| 20-Day Bollinger Lower Band | 1.05 |
| 20-Day Bollinger Middle Band | 1.35 |
| 20-Day Bollinger Upper Band | 1.64 |
| Beta | 0.72 |
| RSI | 75.72 |
| 50-Day SMA | 0.98 |
| 150-Day SMA | 1.51 |
| 200-Day SMA | 1.70 |
System |
|
| Modified | 1/24/2026 2:59:07 AM EST |